Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment

Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.

Published
31 March 2014
By
Michael Carter
South African treatment guidelines need to consider viral load, not CD4 count, to achieve greater impact of treatment as prevention: study

Recommendations about the initiation of antiretroviral therapy (ART) need to change for the use of HIV treatment as prevention to have maximum benefit, according to an international team

Published
27 March 2014
By
Michael Carter
Early treatment reduces viral reservoirs but does not prevent rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys,

Published
21 March 2014
By
Liz Highleyman
Early antiretroviral therapy may limit gut damage and immune activation

Starting antiretroviral therapy (ART) at the earliest stage of HIV infection can help prevent immune cell dysregulation that contributes to destruction of the gut lining and promotes

Published
20 March 2014
By
Liz Highleyman
Raltegravir has the edge over two protease inhibitors in three-drug comparison study

In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor raltegravir (Isentress) proved to

Published
07 March 2014
By
Gus Cairns
Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART

An NRTI-sparing initial regimen of raltegravir (Isentress) plus boosted darunavir (Prezista) worked as well as traditional antiretroviral therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to

Published
06 March 2014
By
Liz Highleyman
Why some people don’t want to start HIV treatment

Researchers in the European Union and Australia conducted research into perceived barriers to starting ART. A primary barrier for HIV-positive people is not feeling sufficiently unwell or having symptoms. Doctors delayed initiation of ART when they perceived patients to be suffering from depression, if there was substance use or if they believed that patients did not understand the need to adhere to HIV medicines.

Published
19 February 2014
From
CATIE
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
Average CD4 cell count at time HIV therapy was started increased among young people in New York City after 2009

The average CD4 cell count at which young people living with HIV in New York City started antiretroviral therapy increased significantly after US guidelines changed in late

Published
29 January 2014
By
Michael Carter
Antiretroviral treatment French guidelines 2013: economics influencing science

In the new French guidelines, economic considerations significantly influence and, in some instances, take precedence over the scientific evidence, leading to guidelines that are significantly different from those of other national and international committees.

Published
27 January 2014
From
Journal of Antimicrobial Chemotherapy
← First12345...61Next →

Filter by country